Cardiol Therapeutics (TSE:CRDL) has released an update.
Cardiol Therapeutics Inc. successfully held its 2024 Annual General and Special Meeting where shareholders endorsed all management resolutions, including the election of eight directors and the appointment of BDO Canada LLP as auditors. The company, known for its clinical-stage development of heart disease therapies, also received approval for its Omnibus Equity Incentive Plan. Cardiol’s lead drug, CardiolRx™, is progressing through clinical studies with the support of the US FDA.
For further insights into TSE:CRDL stock, check out TipRanks’ Stock Analysis page.
